For the best experience, please enable JavaScript in your browser settings. Two US state agencies have acknowledged inaccurate HIV tests in Kenya and several African ...
Pharmaceutical company Gilead Sciences has come under mounting pressure after refusing to sell its breakthrough HIV prevention drug, lenacapavir, directly to Médecins Sans Frontières (MSF), despite ...
Pharmaceutical company Gilead Sciences has come under mounting pressure after refusing to sell its breakthrough HIV prevention drug, lenacapavir, directly to Médecins Sans Frontières (MSF), despite ...
Assoumou is an infectious diseases physician-scientist at Boston Medical Center. Miller is a research data associate within Dr. Assoumou’s I-CARE (Infectious Complications Assessment and Research) lab ...
Add Yahoo as a preferred source to see more of our stories on Google. Gilead Sciences Chief Executive Daniel O'Day. Will he ever reveal why his company is blocking a full global rollout of its ...
"Lenacapavir could be transformative," says Peter Maybarduk, director of the access to medicines program at the nonprofit organization Public Citizen, "if people can get it." What's the main obstacle?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results